Industry Updates for the Psychedelics World | Page 31 of 35

Psychedelics News

Industry

22 Feb 2022

Positive Results in World’s First Trial for DMT Therapy

In the Phase I clinical trial, participants were administered DMT and underwent a 20-minute psychedelic experience - with no serious adverse effects...

By Microdose

Industry

16 Feb 2022

PharmaTher Receives U.S. Patent For Ketamine

Today the company announced that it’s been granted a new patent for the combination of FDA-approved ketamine and PharmaTher’s proprietary betaine anhydrous (“KETABET™”)....

By Jason Najum

Breaking News, Industry

15 Feb 2022

Cybin Inks Deal w Chopra Foundation. Gets Praise From Tony Robbins

The partnership with Chopra will help the sector and in particular, Cybin, who will benefit from the association with this headline name....

By Jason Najum

Industry

14 Feb 2022

Microdose Launches Network of Local Events: Microdose X

These local events will feature talks from experts, artists’ presentations, and opportunities to connect with other psychedelic community members....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

8 Feb 2022

A Look at Small Pharma’s Financial and Business Highlights

Small Pharma, much to its name, has been quietly establishing itself in the psychedelic medicine space....

By Jason Najum

Industry

3 Feb 2022

CEO Interview: Journey Colab

Our conversation with co-founder and CEO Jeeshan Chowdhury gave us insight into a company not only working on an interesting and important indication (mescaline for addiction) but with a social...

By Jason Najum

Industry

2 Feb 2022

PharmaTher Granted FDA Orphan Drug Status for Ketamine

Following up on the recent news that PharmaTher Receives FDA Approval for Ketamine Phase 2 Trial, we now have PharmaTher receving orphan drug status for ketamine to a rare neurological...

By Microdose

Industry

27 Jan 2022

ATAI Launches Discovery Program for Next-Gen Mental Health Treatments

This new platform company is a further step-up in atai’s commitment to next-generation treatment...

By Microdose

Industry

19 Jan 2022

Awakn Life Sciences Signs MOU With MAPS

Agreement to explore a partnership for MDMA-Assisted Therapy for treatment of Alcohol Use Disorder in Europe...

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result